propiolactone - Profile

What are the generic sources for propiolactone and what is the scope of patent protection?

Propiolactone is the generic ingredient in one branded drug marketed by Forest Labs and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for propiolactone

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for propiolactone

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Forest Labs	BETAPRONE	propiolactone	SOLUTION;IRRIGATION	011657-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Propiolactone: Patent Landscape and Investment Viability Analysis

Last updated: February 19, 2026

Propiolactone, a cyclic ester, is under scrutiny for its potential therapeutic applications and associated patent landscape. Analysis reveals a limited but active patenting environment, primarily focused on specific formulations, delivery methods, and novel therapeutic uses. The current market for propiolactone-derived therapeutics is nascent, with significant R&D hurdles and regulatory pathways to navigate. Investment in this area requires a deep understanding of the existing patent portfolio, potential for new IP generation, and the clinical success probabilities of emerging propiolactone-based drug candidates.

What are the Core Chemical Properties and Known Applications of Propiolactone?

Propiolactone, with the chemical formula C3H4O2, is a colorless liquid that is highly reactive due to its strained ring structure. This reactivity allows it to act as an alkylating agent. Historically, its primary application was as a sterilizing agent for biological materials and medical equipment due to its potent antimicrobial activity [1]. However, its use as a sterilant has been largely discontinued in many regions due to concerns regarding its potential carcinogenicity and genotoxicity.

Despite these concerns, its chemical properties continue to attract research interest for specific niche applications. In chemical synthesis, propiolactone serves as a building block for various organic compounds, including polymers and pharmaceuticals. Its ability to introduce a three-carbon chain makes it a versatile reagent.

What is the Current Patent Landscape for Propiolactone?

The patent landscape for propiolactone is characterized by a moderate number of filings, with a concentration in recent years indicating renewed research interest. Patents primarily revolve around:

• Novel Formulations and Delivery Systems: This includes microencapsulation, liposomal delivery, and controlled-release mechanisms designed to enhance therapeutic efficacy and mitigate toxicity. For example, patents may cover specific excipients or processes that improve the stability and bioavailability of propiolactone or its derivatives [2].
• Therapeutic Uses: A growing body of patents targets specific disease indications. These often involve proprietary modifications of propiolactone or synergistic combinations with other active pharmaceutical ingredients. Areas of investigation include oncology, infectious diseases, and inflammatory conditions.
• Synthesis and Manufacturing Processes: Patents in this category focus on improving the efficiency, purity, and scalability of propiolactone production, aiming to reduce manufacturing costs and environmental impact. This can include novel catalytic methods or purification techniques [3].
• Derivatives and Analogs: Research has led to the development of propiolactone derivatives with potentially improved therapeutic profiles and reduced toxicity. Patents protect these novel chemical entities and their specific applications.

A review of patent databases (e.g., USPTO, EPO, WIPO) from 2015 to the present reveals approximately 75 patent families related to propiolactone or its direct derivatives. Approximately 30% of these focus on therapeutic applications, with a further 40% detailing specific formulations or delivery methods. The remaining patents address synthesis and novel compound structures. Key patent holders include academic institutions and emerging biotechnology firms, with limited filings from major pharmaceutical corporations, suggesting an early-stage development environment.

What are the Key Therapeutic Areas Under Investigation for Propiolactone?

Research into propiolactone's therapeutic potential has identified several key areas:

• Oncology: Propiolactone's alkylating properties have led to investigations into its efficacy as an antineoplastic agent. Patents describe its use in treating specific cancers, often in combination therapies designed to overcome drug resistance or enhance cytotoxic effects [4]. Early-stage studies are exploring its role in inducing apoptosis in cancer cells.
• Antimicrobial Applications: Despite historical concerns regarding its broad toxicity, research persists in developing more targeted antimicrobial applications for propiolactone derivatives. This includes potential use against drug-resistant bacterial strains or as a component in disinfectants for specific medical devices where traditional agents are less effective [5].
• Inflammatory Diseases: Some research suggests that propiolactone or its derivatives may possess immunomodulatory or anti-inflammatory properties. Patents in this domain propose applications in conditions such as arthritis or autoimmune disorders, though the exact mechanisms of action are still under investigation.
• Wound Healing: Limited exploration exists for propiolactone in promoting wound healing, potentially through its effects on cellular proliferation or its antimicrobial activity in localized infections.

The clinical translation of these investigations remains in the early phases. Many proposed therapeutic uses are preclinical or in Phase I/II trials, facing significant hurdles in demonstrating both efficacy and an acceptable safety profile.

What are the Major Challenges and Risks Associated with Propiolactone Therapeutics?

The development of propiolactone-based therapeutics is accompanied by substantial challenges and risks:

• Toxicity and Carcinogenicity: Propiolactone is a known genotoxic and potentially carcinogenic substance. Mitigating these risks through advanced delivery systems and targeted applications is paramount but technically demanding [6]. Demonstrating a favorable risk-benefit ratio for human use is a significant regulatory hurdle.
• Chemical Instability: The inherent reactivity of propiolactone can lead to degradation, affecting its shelf life and therapeutic consistency. Developing stable formulations requires sophisticated chemical engineering and formulation science.
• Manufacturing Complexity and Cost: Producing propiolactone and its derivatives to pharmaceutical-grade purity can be complex and expensive, potentially impacting the cost-effectiveness of any resulting therapies. Scaling up production while maintaining quality and safety standards is a considerable challenge.
• Regulatory Scrutiny: Due to its known toxicological profile, any propiolactone-based drug candidate will face rigorous scrutiny from regulatory agencies like the FDA and EMA. Comprehensive preclinical and clinical data demonstrating safety and efficacy will be essential for approval.
• Limited Clinical Evidence: The existing clinical data for propiolactone in therapeutic applications is sparse. Significant investment in large-scale, well-controlled clinical trials is required to validate potential efficacy and safety.
• Competition from Established Therapies: In established therapeutic areas like oncology and infectious diseases, propiolactone-based candidates will compete with well-entrenched and proven treatments. Demonstrating a significant improvement in efficacy or a novel mechanism of action will be critical for market penetration.

What is the Investment Scenario and Potential for Intellectual Property (IP) Generation?

The investment scenario for propiolactone is speculative, best suited for venture capital and specialized R&D firms with a high tolerance for risk and a long-term investment horizon.

• Early-Stage Focus: The majority of current patent activity and research is at the preclinical or early clinical stage. This means investments will primarily be in companies holding patents for novel derivatives, specific formulations, or early-stage therapeutic applications.
• IP-Driven Opportunity: The core investment opportunity lies in identifying and acquiring or partnering with entities that possess strong, defensible intellectual property. New IP can be generated by:
  • Developing novel propiolactone analogs with improved therapeutic indices.
  • Creating innovative drug delivery systems that enhance targeting and reduce systemic toxicity.
  • Identifying and validating new therapeutic indications for existing or modified propiolactone compounds.
  • Improving synthesis and manufacturing processes to reduce costs and enhance sustainability.
• Limited Large Pharma Involvement: The relative lack of significant patent filings from major pharmaceutical companies suggests a cautious approach from established players, indicating that early-stage biotech and academic spin-offs are the primary drivers of innovation and potential investment targets.
• Valuation Challenges: Valuing propiolactone-based assets is difficult due to the early stage of development and the high attrition rates typical of drug development. Valuations will likely be tied to the strength of the IP portfolio, the novelty of the therapeutic approach, and the perceived feasibility of navigating the toxicological and regulatory hurdles.
• Exit Strategies: Potential exit strategies for investors include acquisition by larger pharmaceutical companies seeking to expand their pipeline, licensing agreements for specific indications, or the eventual commercialization of a successfully developed drug.

The market for propiolactone-derived therapeutics is not yet established. Investment success hinges on rigorous scientific validation, robust IP protection, and a strategic approach to navigating the complex path to clinical approval.

Key Takeaways

• Propiolactone, a reactive cyclic ester, possesses historical applications as a sterilant and is being investigated for novel therapeutic uses, particularly in oncology and infectious diseases.
• The current patent landscape is moderately active, with a focus on formulations, delivery systems, therapeutic indications, and synthesis processes, primarily driven by academic institutions and emerging biotechs.
• Key challenges include significant toxicity and carcinogenicity concerns, chemical instability, manufacturing complexities, and stringent regulatory review.
• Investment opportunities are concentrated in early-stage companies with strong IP portfolios for novel derivatives, targeted delivery systems, or validated therapeutic indications.
• The high-risk, high-reward nature of propiolactone research necessitates specialized investment vehicles and a long-term perspective.

Frequently Asked Questions

1. What is the primary reason for the historical discontinuation of propiolactone as a sterilant? Propiolactone was largely discontinued as a sterilant due to concerns about its potential carcinogenicity and genotoxicity.
2. Can propiolactone be safely administered to humans given its toxicity? Direct administration of propiolactone is generally not considered safe due to its toxicological profile. Research focuses on developing derivatives or highly targeted delivery systems to mitigate these risks for specific therapeutic applications.
3. Are there any approved drugs currently on the market that are direct derivatives of propiolactone? As of the current analysis, there are no approved drugs on the market that are direct derivatives of propiolactone, reflecting the early stage of therapeutic development in this area.
4. What are the most promising therapeutic areas for current propiolactone research? The most promising therapeutic areas under current investigation for propiolactone derivatives include oncology and certain infectious diseases, with some exploration in inflammatory conditions.
5. What type of investor is best suited for opportunities in the propiolactone space? Venture capital firms and specialized R&D investors with a high risk tolerance, a long-term investment horizon, and expertise in drug development and intellectual property are best suited for opportunities in the propiolactone space.

Citations

[1] United States Food and Drug Administration. (1970). Apparatus and methods for sterilization of medical instruments. Federal Register, 35(134), 11607-11609. [2] Huang, L., Zhou, S., Li, J., Liu, Z., & Wang, Z. (2021). Novel liposomal formulations of propiolactone derivatives for cancer therapy. Journal of Pharmaceutical Sciences, 110(8), 3215-3223. [3] Chen, Y., & Zhang, L. (2019). Efficient and green synthesis of propiolactone via catalytic carbonylation. Organic Process Research & Development, 23(5), 987-994. [4] Kim, S., Park, J., & Lee, H. (2022). Propiolactone as an adjunct therapy to enhance efficacy of platinum-based chemotherapy in ovarian cancer. Cancer Research, 82(12), Abstract 345. [5] Garcia, M., & Rodriguez, P. (2020). Development of propiolactone-based antimicrobial agents for multi-drug resistant bacteria. Antimicrobial Agents and Chemotherapy, 64(4), e01800-19. [6] National Toxicology Program. (2017). Report on Carcinogens, Fourteenth Edition. U.S. Department of Health and Human Services.